



**Lannett Company, Inc.**

9000 State Road, Philadelphia, PA 19136

Telephone: 215-333-9000 • Fax: 215-333-9004

www.lannett.com

4382 13 007

October 2, 2013

Division of Dockets Management  
U.S. Food and Drug Administration  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**SUITABILITY PETITION**

Dear Sir/Madam:

The undersigned submits this petition under Sections 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA, or the "Act") and 21 CFR § 314.93 to request that the Commissioner of Food and Drugs determine that an Abbreviated New Drug Application (ANDA) for Acetazolamide Extended-Release Tablets may be submitted based on the Reference Listed Drug (RLD) DIAMOX® SEQUELS® (Acetazolamide Extended-Release Capsules).

**A. Action Requested**

The petitioner seeks a determination from the Commissioner of Food and Drugs that a tablet dosage form may be submitted as an ANDA versus the RLD capsule dosage form for DIAMOX® SEQUELS® (Acetazolamide Extended-Release Capsules). **Attachment 1** contains a copy of the pertinent pages from the electronic version of the "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations" which lists the approved RLD referenced in this petition.

**B. Statement of Grounds**

This petition requests a change in the dosage form from the RLD. Both the RLD and the proposed drug product are solid oral dosage forms with the same route of administration. The proposed drug product is expected to have the same therapeutic effect as the RLD when administered to patients under the same conditions of use.

The package insert for the RLD is provided in **Attachment 2**. The proposed package insert for the Lannett product is provided in **Attachment 3**.

FDA - 2013 - P - 1296

2013-2411  
CP

A Pediatric Research Equity Act (PREA) Waiver Request is provided in **Attachment 4**.

For all the reasons mentioned above, the Commissioner should approve this petition no later than 90 days after this petition is submitted and authorize the submission of an ANDA for the proposed drug product.

**C. Environmental Impact**

The actions requested herein are subject to categorical exclusion under 21 CFR §25.31(a).

**D. Economic Impact**


An economic impact statement will be submitted upon request should the Commissioner determine such assessment is necessary in evaluating this petition.

**E. Certification**

The undersigned certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner which are unfavorable to the petition.

Please direct any questions or comments regarding this submission to my attention via phone at (215) 333-9000, ext. 2277, e-mail at [esabo@lannett.com](mailto:esabo@lannett.com) or facsimile at (215) 624-2126.

Sincerely,



Ernest J. Sabo  
Vice President, Regulatory & Chief Compliance Officer  
Lannett Company, Inc.  
13200 Townsend Road  
Philadelphia, PA 19154

From: (215) 333-9000  
Kristie Stephens  
Lannett Company, Inc.  
9000 State Road

Origin ID: IRCA



Philadelphia, PA 19136

Ship Date: 02OCT13  
ActWgt: 2.0 LB  
CAD: 101271069/INET3430

Delivery Address Bar Code




SHIP TO: (301) 827-6860

BILL SENDER

Division of Dockets Management  
Food and Drug Administration  
5630 Fishers Lane, Room 1061

Ref #  
Invoice #  
PO #  
Dept #

RT 608 1 D  
4254  
10.04  
20852



FRI - 04 OCT AA  
\*\* 2DAY \*\*

TRK# 7968 2110 4254

0201

1R NSFA

20852  
MD-US  
IAD



514014818140F

*The World On Time.*

# Small Box

Align bottom of Peel and Stick Airbill or Pouch here.